Publication | Closed Access

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

72-Hour InfusionOncologyAdvanced CancersMedicinePharmacotherapyAnti-cancer AgentCancer TreatmentSmall-molecule InhibitorPharmacologyRadiation OncologyNovel TherapyCancer Research